

# Alfredo Berruti

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3809571/publications.pdf>

Version: 2024-02-01

173  
papers

6,431  
citations

109137

35  
h-index

74018

75  
g-index

176  
all docs

176  
docs citations

176  
times ranked

6237  
citing authors

#	ARTICLE	IF	CITATIONS
1	Combination Chemotherapy in Advanced Adrenocortical Carcinoma. <i>New England Journal of Medicine</i> , 2012, 366, 2189-2197.	13.9	692
2	Adjuvant Mitotane Treatment for Adrenocortical Carcinoma. <i>New England Journal of Medicine</i> , 2007, 356, 2372-2380.	13.9	679
3	European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors. <i>European Journal of Endocrinology</i> , 2018, 179, G1-G46.	1.9	559
4	Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. <i>Lancet Oncology</i> , The, 2015, 16, 426-435.	5.1	272
5	Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. <i>Endocrine-Related Cancer</i> , 2005, 12, 657-666.	1.6	255
6	Pathologic Complete Response As a Potential Surrogate for the Clinical Outcome in Patients With Breast Cancer After Neoadjuvant Therapy: A Meta-Regression of 29 Randomized Prospective Studies. <i>Journal of Clinical Oncology</i> , 2014, 32, 3883-3891.	0.8	194
7	Plasma Concentrations of o,p,p'-DDD, o,p,p'-DDA, and o,p,p'-DDE as Predictors of Tumor Response to Mitotane in Adrenocortical Carcinoma: Results of a Retrospective ENS@T Multicenter Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 1844-1851.	1.8	160
8	Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly. <i>Endocrine-Related Cancer</i> , 2008, 15, 1043-1053.	1.6	141
9	Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study. <i>Endocrine-Related Cancer</i> , 2010, 17, 445-453.	1.6	138
10	Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma. <i>European Journal of Endocrinology</i> , 2012, 166, 451-458.	1.9	132
11	Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. <i>Cancer</i> , 1998, 83, 2194-2200.	2.0	121
12	Prognostic Role of Overt Hypercortisolism in Completely Operated Patients with Adrenocortical Cancer. <i>European Urology</i> , 2014, 65, 832-838.	0.9	121
13	Long-Term Outcomes of Adjuvant Mitotane Therapy in Patients With Radically Resected Adrenocortical Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 1358-1365.	1.8	108
14	Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1652-1664.	5.1	108
15	Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. <i>Journal of Urology</i> , 2002, 167, 2361-7; discussion 2367.	0.2	104
16	Chromogranin A Expression in Patients With Hormone Naïve Prostate Cancer Predicts the Development of Hormone Refractory Disease. <i>Journal of Urology</i> , 2007, 178, 838-843.	0.2	86
17	Gemcitabine-Based Chemotherapy in Adrenocortical Carcinoma: A Multicenter Study of Efficacy and Predictive Factors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 4323-4332.	1.8	79
18	Immune-related Adverse Events and Survival in Solid Tumors Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. <i>Journal of Immunotherapy</i> , 2020, 43, 1-7.	1.2	75

#	ARTICLE	IF	CITATIONS
19	Circulating Tumor Cells in Patients with Recurrent or Metastatic Head and Neck Carcinoma: Prognostic and Predictive Significance. <i>PLoS ONE</i> , 2014, 9, e103918.	1.1	69
20	Validation of the prognostic role of the "Helsinki Score" in 225 cases of adrenocortical carcinoma. <i>Human Pathology</i> , 2017, 62, 1-7.	1.1	69
21	Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015, 34, 10.	3.5	65
22	GPNMB/OA protein increases the invasiveness of human metastatic prostate cancer cell lines DU145 and PC3 through MMP-2 and MMP-9 activity. <i>Experimental Cell Research</i> , 2014, 323, 100-111.	1.2	61
23	Outcome of patients with lung adenocarcinoma with transformation to small-cell lung cancer following tyrosine kinase inhibitors treatment: A systematic review and pooled analysis. <i>Cancer Treatment Reviews</i> , 2017, 59, 117-122.	3.4	61
24	Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: Results from a large patient cohort. <i>European Journal of Cancer</i> , 2013, 49, 2134-2142.	1.3	60
25	Follow-up after gastrectomy for cancer: the Charter Scaligero Consensus Conference. <i>Gastric Cancer</i> , 2016, 19, 15-20.	2.7	51
26	Assessment of the Safety of Glucocorticoid Regimens in Combination With Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer. <i>JAMA Oncology</i> , 2019, 5, 1159.	3.4	50
27	Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509). <i>Journal of Clinical Oncology</i> , 2021, 39, 2304-2312.	0.8	49
28	CT texture analysis for prediction of EGFR mutational status and ALK rearrangement in patients with non-small cell lung cancer. <i>Radiologia Medica</i> , 2021, 126, 786-794.	4.7	46
29	Pitfalls in the diagnosis of adrenocortical tumors: a lesson from 300 consultation cases. <i>Human Pathology</i> , 2015, 46, 1799-1807.	1.1	44
30	Texture features of colorectal liver metastases on pretreatment contrast-enhanced CT may predict response and prognosis in patients treated with bevacizumab-containing chemotherapy: a pilot study including comparison with standard chemotherapy. <i>Radiologia Medica</i> , 2019, 124, 877-886.	4.7	42
31	Testosterone Levels and Prostate Cancer Prognosis: Systematic Review and Meta-analysis. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 165-175.e2.	0.9	41
32	Outcome of EGFR-mutated adenocarcinoma NSCLC patients with changed phenotype to squamous cell carcinoma after tyrosine kinase inhibitors: A pooled analysis with an additional case. <i>Lung Cancer</i> , 2019, 127, 12-18.	0.9	40
33	Patient frailty predicts worse perioperative outcomes and higher cost after radical cystectomy. <i>Surgical Oncology</i> , 2020, 32, 8-13.	0.8	39
34	Immunotherapy failure in adrenocortical cancer: where next?. <i>Endocrine Connections</i> , 2018, 7, E5-E8.	0.8	39
35	Efficacy of the EDP-M Scheme Plus Adjunctive Surgery in the Management of Patients with Advanced Adrenocortical Carcinoma: The Brescia Experience. <i>Cancers</i> , 2020, 12, 941.	1.7	38
36	Decision-making for adrenocortical carcinoma: surgical, systemic, and endocrine management options. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 1125-1133.	1.1	34

#	ARTICLE	IF	CITATIONS
37	Molecular Drivers of Potential Immunotherapy Failure in Adrenocortical Carcinoma. <i>Journal of Oncology</i> , 2019, 2019, 1-7.	0.6	34
38	Morphometric vertebral fractures in breast cancer patients treated with adjuvant aromatase inhibitor therapy: A cross-sectional study. <i>Bone</i> , 2017, 97, 147-152.	1.4	33
39	CT texture analysis as predictive factor in metastatic lung adenocarcinoma treated with tyrosine kinase inhibitors (TKIs). <i>European Journal of Radiology</i> , 2018, 109, 130-135.	1.2	33
40	When Less Is More: Specific Capture and Analysis of Tumor Exosomes in Plasma Increases the Sensitivity of Liquid Biopsy for Comprehensive Detection of Multiple Androgen Receptor Phenotypes in Advanced Prostate Cancer Patients. <i>Biomedicines</i> , 2020, 8, 131.	1.4	33
41	Antisecretive and Antitumor Activity of Abiraterone Acetate in Human Adrenocortical Cancer: A Preclinical Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 4594-4602.	1.8	31
42	Activity and safety of temozolomide in advanced adrenocortical carcinoma patients. <i>European Journal of Endocrinology</i> , 2019, 181, 681-689.	1.9	30
43	Emerging drugs for adrenocortical carcinoma. <i>Expert Opinion on Emerging Drugs</i> , 2008, 13, 497-509.	1.0	29
44	Palbociclib inhibits proliferation of human adrenocortical tumor cells. <i>Endocrine</i> , 2018, 59, 213-217.	1.1	28
45	Immune-checkpoint inhibitors and metastatic prostate cancer therapy: Learning by making mistakes. <i>Cancer Treatment Reviews</i> , 2020, 88, 102057.	3.4	28
46	Contemporary Age-adjusted Incidence and Mortality Rates of Renal Cell Carcinoma: Analysis According to Gender, Race, Stage, Grade, and Histology. <i>European Urology Focus</i> , 2021, 7, 644-652.	1.6	28
47	ecancermedalscience. <i>Ecancermedalscience</i> , 2014, 8, 463.	0.6	26
48	Association of Fat Body Mass With Vertebral Fractures in Postmenopausal Women With Early Breast Cancer Undergoing Adjuvant Aromatase Inhibitor Therapy. <i>JAMA Network Open</i> , 2019, 2, e1911080.	2.8	26
49	Cytotoxic activity of gemcitabine, alone or in combination with mitotane, in adrenocortical carcinoma cell lines. <i>Molecular and Cellular Endocrinology</i> , 2014, 382, 1-7.	1.6	25
50	Transformation of Prostate Adenocarcinoma Into Small-Cell Neuroendocrine Cancer Under Androgen Deprivation Therapy: Much Is Achieved But More Information Is Needed. <i>Journal of Clinical Oncology</i> , 2019, 37, 350-351.	0.8	25
51	Final results of the TALENT trial (GETNE1509): a prospective multicohort phase II study of lenvatinib in patients (pts) with G1/G2 advanced pancreatic (panNETs) and gastrointestinal (giNETs) neuroendocrine tumors (NETs).. <i>Journal of Clinical Oncology</i> , 2019, 37, 4106-4106.	0.8	25
52	Topoisomerase 2 $\alpha$ and thymidylate synthase expression in adrenocortical cancer. <i>Endocrine-Related Cancer</i> , 2017, 24, 319-327.	1.6	24
53	Unwanted Hormonal and Metabolic Effects of Postoperative Adjuvant Mitotane Treatment for Adrenocortical Cancer. <i>Cancers</i> , 2020, 12, 2615.	1.7	24
54	The prognostic power of 18F-FDG PET/CT extends to estimating systemic treatment response duration in metastatic castration-resistant prostate cancer (mCRPC) patients. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 1198-1207.	2.0	24

#	ARTICLE	IF	CITATIONS
55	RRM1 modulates mitotane activity in adrenal cancer cells interfering with its metabolism. <i>Molecular and Cellular Endocrinology</i> , 2015, 401, 105-110.	1.6	23
56	Bone health management in the continuum of prostate cancer disease: a review of the evidence with an expert panel opinion. <i>ESMO Open</i> , 2020, 5, e000652.	2.0	23
57	Treatment With 90Y/177Lu-DOTATOC in Patients With Metastatic Adrenocortical Carcinoma Expressing Somatostatin Receptors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e1-e5.	1.8	22
58	Bone Mineral Density and FRAX Score May Not Predict Fracture Risk in Patients With Cancer Undergoing Hormone Deprivation Therapies. <i>Journal of Clinical Oncology</i> , 2020, 38, 3363-3366.	0.8	22
59	Higher Risk of Fragility Fractures in Prostate Cancer Patients Treated with Combined Radium-223 and Abiraterone: Prednisone May Be the Culprit. <i>European Urology</i> , 2019, 75, 894-895.	0.9	22
60	Second line treatment of recurrent glioblastoma with sunitinib: results of a phase II study and systematic review of literature. <i>Journal of Neurosurgical Sciences</i> , 2019, 63, 458-467.	0.3	22
61	Adding metyrapone to chemotherapy plus mitotane for Cushing's syndrome due to advanced adrenocortical carcinoma. <i>Endocrine</i> , 2018, 61, 169-172.	1.1	21
62	In vitro antitumor activity of progesterone in human adrenocortical carcinoma. <i>Endocrine</i> , 2019, 63, 592-601.	1.1	21
63	Complication rates, failure to rescue and in-hospital mortality after cytoreductive nephrectomy in the older patients. <i>Journal of Geriatric Oncology</i> , 2020, 11, 718-723.	0.5	21
64	Effects of Medical Treatment of Prostate Cancer on Bone Health. <i>Trends in Endocrinology and Metabolism</i> , 2021, 32, 135-158.	3.1	21
65	Androgen deprivation modulates gene expression profile along prostate cancer progression. <i>Human Pathology</i> , 2016, 56, 81-88.	1.1	20
66	Ki-67 Index of 55% Distinguishes Two Groups of Bronchopulmonary Pure and Composite Large Cell Neuroendocrine Carcinomas with Distinct Prognosis. <i>Neuroendocrinology</i> , 2021, 111, 475-489.	1.2	19
67	Expression of SOAT1 in Adrenocortical Carcinoma and Response to Mitotane Monotherapy: An ENSAT Multicenter Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 2642-2653.	1.8	18
68	Detailed genomic characterization identifies high heterogeneity and histotype-specific genomic profiles in adrenocortical carcinomas. <i>Modern Pathology</i> , 2018, 31, 1257-1269.	2.9	17
69	Survival and Complication Rates of Metastasectomy in Patients With Metastatic Renal Cell Carcinoma Treated Exclusively With Targeted Therapy: A Combined Population-based Analysis. <i>Anticancer Research</i> , 2019, 39, 4357-4361.	0.5	17
70	Cytotoxic Effect of Trabectedin In Human Adrenocortical Carcinoma Cell Lines and Primary Cells. <i>Cancers</i> , 2020, 12, 928.	1.7	16
71	Results of the ADIUVO Study, the First Randomized Trial on Adjuvant Mitotane in Adrenocortical Carcinoma Patients. <i>Journal of the Endocrine Society</i> , 2021, 5, A166-A167.	0.1	16
72	Morbidity and mortality of bone metastases in advanced adrenocortical carcinoma: a multicenter retrospective study. <i>European Journal of Endocrinology</i> , 2019, 180, 311-320.	1.9	16

#	ARTICLE	IF	CITATIONS
73	A Comprehensive Investigation of Steroidogenic Signaling in Classical and New Experimental Cell Models of Adrenocortical Carcinoma. <i>Cells</i> , 2022, 11, 1439.	1.8	16
74	Favorable Response of Metastatic Adrenocortical Carcinoma to Etoposide, Adriamycin and Cisplatin (EAP) Chemotherapy. Report of two Cases. <i>Tumori</i> , 1992, 78, 345-348.	0.6	15
75	Plasma Androgen Receptor Copy Number Status at Emergence of Metastatic Castration-Resistant Prostate Cancer: A Pooled Multicohort Analysis. <i>JCO Precision Oncology</i> , 2019, 3, 1-13.	1.5	15
76	Cytotoxic Effect of Progesterone, Tamoxifen and Their Combination in Experimental Cell Models of Human Adrenocortical Cancer. <i>Frontiers in Endocrinology</i> , 2021, 12, 669426.	1.5	15
77	Inhibition of Survivin Is Associated with Zoledronic Acid-induced Apoptosis of Prostate Cancer Cells. <i>Anticancer Research</i> , 2016, 36, 913-20.	0.5	15
78	Systemic therapies in patients with advanced well-differentiated pancreatic neuroendocrine tumors (PanNETs): When cytoreduction is the aim. A critical review with meta-analysis. <i>Cancer Treatment Reviews</i> , 2018, 71, 39-46.	3.4	14
79	Renal cell carcinoma incidence rates and trends in young adults aged 20-39 years. <i>Cancer Epidemiology</i> , 2020, 67, 101762.	0.8	14
80	What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question. <i>Journal of Personalized Medicine</i> , 2021, 11, 269.	1.1	14
81	Adjuvant platinum-based chemotherapy in radically resected adrenocortical carcinoma: a cohort study. <i>British Journal of Cancer</i> , 2021, 125, 1233-1238.	2.9	14
82	Are we failing in treatment of adrenocortical carcinoma? Lights and shadows of molecular signatures. <i>Current Opinion in Endocrine and Metabolic Research</i> , 2019, 8, 80-87.	0.6	13
83	In vitro cytotoxicity of cabazitaxel in adrenocortical carcinoma cell lines and human adrenocortical carcinoma primary cell cultures. <i>Molecular and Cellular Endocrinology</i> , 2019, 498, 110585.	1.6	13
84	The Circadian Rhythm of Breakthrough Pain Episodes in Terminally-ill Cancer Patients. <i>Cancers</i> , 2019, 11, 18.	1.7	13
85	Panniculitis and vitiligo occurring during BRAF and MEK inhibitors combination in advanced melanoma patients: Potential predictive role of treatment efficacy. <i>PLoS ONE</i> , 2019, 14, e0214884.	1.1	13
86	Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 319-326.	1.4	12
87	Prognostic Factors in Patients Receiving Third Line Targeted Therapy for Metastatic Renal Cell Carcinoma. <i>Journal of Urology</i> , 2015, 193, 1905-1910.	0.2	11
88	Prognostic and predictive value of histogram analysis in patients with non-small cell lung cancer refractory to platinum treated by nivolumab: A multicentre retrospective study. <i>European Journal of Radiology</i> , 2019, 118, 251-256.	1.2	11
89	Excess of second tumors in denosumab-treated patients: a metabolic hypothesis. <i>Future Oncology</i> , 2019, 15, 2319-2321.	1.1	11
90	Adrenocortical Carcinoma Xenograft in Zebrafish Embryos as a Model To Study the In Vivo Cytotoxicity of Abiraterone Acetate. <i>Endocrinology</i> , 2019, 160, 2620-2629.	1.4	11

#	ARTICLE	IF	CITATIONS
91	ENSAT registry-based randomized clinical trials for adrenocortical carcinoma. <i>European Journal of Endocrinology</i> , 2021, 184, R51-R59.	1.9	11
92	Changes in body composition and lipid profile in prostate cancer patients without bone metastases given Degarelix treatment: the BLADE prospective cohort study. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 852-859.	2.0	11
93	The long and winding road to effective immunotherapy in patients with adrenocortical carcinoma. <i>Future Oncology</i> , 2020, 16, 3017-3020.	1.1	11
94	Management of Severe Cushing Syndrome Induced by Adrenocortical Carcinoma with Abiraterone Acetate: A Case Report. <i>AACE Clinical Case Reports</i> , 2016, 2, e337-e341.	0.4	11
95	CYP11B1 has no role in mitotane action and metabolism in adrenocortical carcinoma cells. <i>PLoS ONE</i> , 2018, 13, e0196931.	1.1	10
96	Biological effect of neoadjuvant androgen-deprivation therapy assessed on specimens from radical prostatectomy: a systematic review. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2018, 70, 370-379.	3.9	10
97	Contemporary Cytoreductive Nephrectomy Provides Survival Benefit in Clear-cell Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e730-e738.	0.9	9
98	Systemic Therapy in Locally Advanced or Metastatic Adrenal Cancers: A Critical Appraisal and Clinical Trial Update. <i>European Urology Focus</i> , 2016, 1, 298-300.	1.6	8
99	Circannual variation of mitotane and its metabolites plasma levels in patients with adrenocortical carcinoma. <i>Journal of Pharmacy and Pharmacology</i> , 2017, 69, 1524-1530.	1.2	8
100	Eight-week interval in flushing and locking port-a-cath in cancer patients: A single institution experience and systematic review. <i>European Journal of Cancer Care</i> , 2019, 28, e12978.	0.7	8
101	Treatment paths for localised prostate cancer in Italy: The results of a multidisciplinary, observational, prospective study (Pros-IT CNR). <i>PLoS ONE</i> , 2019, 14, e0224151.	1.1	8
102	Differences in short-term outcomes between open versus robot-assisted radical cystectomy in frail malnourished patients. <i>European Journal of Surgical Oncology</i> , 2020, 46, 1347-1352.	0.5	8
103	Baseline prognostic factors affecting survival in recurrent and/or metastatic salivary gland adenoid cystic carcinoma. <i>Oral Oncology</i> , 2022, 126, 105764.	0.8	8
104	Analysis of Circulating Tumor Cells in Prostate Cancer Patients at PSA Recurrence and Review of the Literature. <i>Anticancer Research</i> , 2016, 36, 2975-81.	0.5	8
105	Ribociclib Cytotoxicity Alone or Combined With Progesterone and/or Mitotane in in Vitro Adrenocortical Carcinoma Cells. <i>Endocrinology</i> , 2022, 163, .	1.4	8
106	Neoadjuvant Treatment Approach: The Rosetta Stone for Breast Cancer?. <i>Journal of the National Cancer Institute Monographs</i> , 2015, 2015, 32-35.	0.9	7
107	Resistance to Hormonal Therapy in Prostate Cancer. <i>Handbook of Experimental Pharmacology</i> , 2017, 249, 181-194.	0.9	7
108	Bone metastases from head and neck malignancies: Prognostic factors and skeletal-related events. <i>PLoS ONE</i> , 2019, 14, e0213934.	1.1	7

#	ARTICLE	IF	CITATIONS
109	Abiraterone acetate exerts a cytotoxic effect in human prostate cancer cell lines. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2019, 392, 729-742.	1.4	7
110	Adrenocortical Carcinoma and CT Assessment of Therapy Response: The Value of Combining Multiple Criteria. <i>Cancers</i> , 2020, 12, 1395.	1.7	7
111	Clinical Prognostic Factors in Patients With Metastatic Adrenocortical Carcinoma Treated With Second Line Gemcitabine Plus Capecitabine Chemotherapy. <i>Frontiers in Endocrinology</i> , 2021, 12, 624102.	1.5	7
112	Estrogen-Like Effect of Mitotane Explained by Its Agonist Activity on Estrogen Receptor- $\alpha$ . <i>Biomedicines</i> , 2021, 9, 681.	1.4	7
113	Supportive therapies in patients with advanced adrenocortical carcinoma submitted to standard EDP-M regimen. <i>Endocrine</i> , 2022, 77, 438-443.	1.1	7
114	Clinical Management of Neuroendocrine Neoplasms in Clinical Practice: A Formal Consensus Exercise. <i>Cancers</i> , 2022, 14, 2501.	1.7	7
115	Testosterone serum levels and prostate cancer prognosis: the double face of Janus. <i>Future Oncology</i> , 2014, 10, 1113-1115.	1.1	6
116	Effect of Primary Letrozole Treatment on Tumor Expression of mTOR and HIF-1 $\alpha$ and Relation to Clinical Response. <i>Journal of the National Cancer Institute Monographs</i> , 2015, 2015, 64-66.	0.9	6
117	Hepatoprotective effect of N-acetylcysteine in trabectedin-induced liver toxicity in patients with advanced soft tissue sarcoma. <i>Supportive Care in Cancer</i> , 2018, 26, 2929-2935.	1.0	6
118	Biological bases of radical prostatectomy in the management of prostate cancer patients with oligometastatic disease. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2018, 70, 539-542.	3.9	6
119	FGF/FGFR signaling in adrenocortical development and tumorigenesis: novel potential therapeutic targets in adrenocortical carcinoma. <i>Endocrine</i> , 2022, 77, 411-418.	1.1	6
120	Regression of advanced neuroendocrine tumors among patients receiving placebo. <i>Endocrine-Related Cancer</i> , 2017, 24, L13-L16.	1.6	5
121	Abiraterone and prednisone therapy may cause severe hypoglycemia when administered to prostate cancer patients with type 2 diabetes receiving glucose-lowering agents. <i>Endocrine</i> , 2019, 64, 724-726.	1.1	5
122	Bladder cancer incidence rates and trends in young adults aged 20-39 years. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 934.e11-934.e19.	0.8	5
123	The Spread of SARS-CoV-2 Infection Among the Medical Oncology Staff of ASST Spedali Civili of Brescia: Efficacy of Preventive Measures. <i>Frontiers in Oncology</i> , 2020, 10, 1574.	1.3	5
124	Should everolimus be stopped after radiological progression in metastatic insulinoma? A "consensus" point of view. <i>Endocrine</i> , 2020, 69, 481-484.	1.1	5
125	Efficacy of the DigniCap System in preventing chemotherapy-induced alopecia in breast cancer patients is not related to patient characteristics or side effects of the device. <i>International Journal of Nursing Practice</i> , 2021, 27, e12888.	0.8	5
126	Case Report: Exceptional Response to Second Line Temozolomide Therapy in a Patient With Metastatic Adrenocortical Carcinoma. <i>Frontiers in Endocrinology</i> , 2021, 12, 674039.	1.5	5



#	ARTICLE	IF	CITATIONS
127	Efficacy of Immune Checkpoint Inhibitors in Rare Tumours: A Systematic Review. <i>Frontiers in Immunology</i> , 2021, 12, 720748.	2.2	5
128	Sequential Therapy with IMiD's in Relapsed-Refractory Multiple Myeloma Patients.. <i>Blood</i> , 2009, 114, 2888-2888.	0.6	5
129	Progression-free survival (PFS) and subgroups analyses of lenvatinib in patients (pts) with G1/G2 advanced pancreatic (panNETs) and gastrointestinal (giNETs) neuroendocrine tumors (NETs): Updated results from the phase II TALENT trial (GETNE 1509).. <i>Journal of Clinical Oncology</i> , 2019, 37, 332-332.	0.8	5
130	Ovarian Strumal Carcinoid: Case Report, Systematic Literature Review and Pooled Analysis. <i>Frontiers in Endocrinology</i> , 2022, 13, 871210.	1.5	5
131	Non-metastatic ductal adenocarcinoma of the prostate: pattern of care from an uro-oncology multidisciplinary group. <i>World Journal of Urology</i> , 2021, 39, 1161-1170.	1.2	4
132	Microvascular Structural Alterations in Cancer Patients Treated With Antiangiogenic Drugs. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 651594.	1.1	4
133	Cisplatin Cytotoxicity in Human Testicular Germ Cell Tumor Cell Lines Is Enhanced by the CDK4/6 Inhibitor Palbociclib. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 316-324.	0.9	4
134	Different management of adrenocortical carcinoma in children compared to adults: is it time to share guidelines?. <i>Endocrine</i> , 2021, 74, 475-477.	1.1	4
135	Adjuvant bisphosphonates in patients with breast cancer: does the potency matter?. <i>Future Oncology</i> , 2015, 11, 2853-2856.	1.1	3
136	Docetaxel plus androgen deprivation withdrawal may restore sensitivity to luteinizing hormone-releasing hormone analog therapy in castration-resistant prostate cancer patients. <i>Endocrine</i> , 2016, 54, 830-833.	1.1	3
137	When Should Everolimus Be Administered in the Natural History of Pancreatic Neuroendocrine Tumors?. <i>Journal of Clinical Oncology</i> , 2017, 35, 1487-1488.	0.8	3
138	Antineoplastic activity of artemisinin in adrenocortical carcinoma. <i>Endocrine</i> , 2019, 66, 425-427.	1.1	3
139	Hyperthermic Intraperitoneal Chemotherapy for Primary or Recurrent Adrenocortical Carcinoma. A Single Center Study. <i>Cancers</i> , 2020, 12, 969.	1.7	3
140	Maintenance versus discontinuation of androgen deprivation therapy during continuous or intermittent docetaxel administration in castration-resistant prostate cancer patients: A multicentre, randomised Phase III study by the Piemonte Oncology Network. <i>European Journal of Cancer</i> , 2021, 155, 127-135.	1.3	3
141	Rate of venous thromboembolism and atrial fibrillation in a real-world case series of advanced cancer patients: the CaTEV Study. <i>Journal of Cardiovascular Medicine</i> , 2021, 22, 444-452.	0.6	3
142	Molecular genotyping of adrenocortical carcinoma: a systematic analysis of published literature 2019-2021. <i>Current Opinion in Oncology</i> , 2022, 34, 19-28.	1.1	3
143	Is androgen deprivation therapy protective against SARS-CoV-2 infection and related complications in prostate cancer patients?. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2020, 72, 778-779.	3.9	3
144	Progression of Vertebral Fractures in Patients with Adrenocortical Carcinoma Undergoing Mitotane Therapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e2167-e2176.	1.8	3

#	ARTICLE	IF	CITATIONS
145	Development and Validation of a Patient-Physician Relationship Index in the Advanced Cancer Setting. <i>Tumori</i> , 2007, 93, 485-490.	0.6	2
146	A current perspective on treatment of adrenocortical carcinoma. <i>Expert Opinion on Orphan Drugs</i> , 2014, 2, 911-921.	0.5	2
147	Should Adjuvant Weekly Paclitaxel Be Considered Less Efficacious Than Anthracyclines Plus Cyclophosphamide for Lower-Risk Patients With Early-Stage Breast Cancer?. <i>Journal of Clinical Oncology</i> , 2015, 33, 290-290.	0.8	2
148	Management of Patients with Castration-Resistant Prostate Cancer (CRPC): Results of an Italian Survey Using the Delphi Method. <i>Tumori</i> , 2016, 102, 514-520.	0.6	2
149	Adrenocortical Carcinoma. <i>Cancers</i> , 2021, 13, 1077.	1.7	2
150	Letter to the Editor From Berruti et al: "Cyto-reductive Surgery of the Primary Tumor in Metastatic Adrenocortical Carcinoma: Impact on Patients' Survival". <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, , .	1.8	2
151	Psychological and Emotional Impact of COVID-19 Pandemic on People Living with Chronic Disease: HIV and Cancer. <i>AIDS and Behavior</i> , 2022, 26, 2920-2930.	1.4	2
152	Cytotoxic effects of targeted agent alone or with chemotherapy in the treatment of adenoid cystic carcinoma: a preclinical study. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
153	Molecular target agents in adrenocortical carcinoma: rationale and difficulties in trial design. <i>International Journal of Endocrine Oncology</i> , 2014, 1, 31-34.	0.4	1
154	IFN- $\gamma$ in advanced well-differentiated neuroendocrine tumors: the neglected drug?. <i>Future Oncology</i> , 2018, 14, 897-899.	1.1	1
155	Frequency and outcome of SARS-CoV-2 infection in patients with adrenocortical carcinoma followed at a reference center in Italy. <i>Endocrine</i> , 2021, 72, 20-23.	1.1	1
156	International randomized, double-blind, placebo-controlled, phase 3 study of linsitinib (OSI-906, L) in patients (pts) with locally advanced or metastatic adrenocortical carcinoma (ACC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 4507-4507.	0.8	1
157	A randomized trial of abiraterone acetate (AA) administered with 1 of 4 glucocorticoid (GC) regimens in metastatic castration-resistant prostate cancer (mCRPC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2016, 34, 261-261.	0.8	1
158	Accurate Triage of Oncological Patients for Safely Continuing Cancer Therapy During the SARS-CoV-2 Pandemic. <i>Frontiers in Oncology</i> , 2021, 11, 707346.	1.3	1
159	Amiloride effects on abiraterone antiproliferative activity in prostate cancer cells in vitro and on clinical management of abiraterone induced mineralocorticoid excess syndrome.. <i>Journal of Clinical Oncology</i> , 2016, 34, 175-175.	0.8	1
160	Neoadjuvant androgen deprivation therapy through intense inhibition of the androgen target: "Midsummer Night's Dream" or "Much Ado About Nothing"? <i>Annals of Translational Medicine</i> , 2019, 7, S230-S230.		1
161	Is BMI a reliable prognostic parameter in metastatic prostate cancer patients?. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 797-797.	2.0	1
162	Trabectedin in advanced retroperitoneal well differentiated/dedifferentiated liposarcoma and leiomyosarcoma (TRAVELL): Results of a phase 2 study from Italian sarcoma group (ISG).. <i>Journal of Clinical Oncology</i> , 2022, 40, 11575-11575.	0.8	1

#	ARTICLE	IF	CITATIONS
163	Maintenance everolimus beyond progression in pancreatic NET to control insulinoma syndrome. <i>Endocrine</i> , 2021, 71, 258-258.	1.1	0
164	Could a comprehensive urinary endogenous steroidal profile improve the accuracy of prostate-specific antigen screening?. <i>Minerva Urology and Nephrology</i> , 2021, 73, 130-131.	1.3	0
165	Gonadal function in male patients with metastatic renal cell cancer treated with sunitinib: Effects of testosterone replacement on quality of life.. <i>Journal of Clinical Oncology</i> , 2016, 34, 525-525.	0.8	0
166	Clinical qualification of plasma androgen receptor (p <i>&gt;AR&lt;/i&gt;) status and outcome on abiraterone acetate (AA) plus prednisone or dexamethasone (+P/D) in a phase II multi-institutional study in metastatic castration resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i>, 2018, 36, 5067-5067.</i>	0.8	0
167	The impact of body composition on vertebral fractures during aromatase inhibitors therapy: A cross-sectional study.. <i>Journal of Clinical Oncology</i> , 2018, 36, e12504-e12504.	0.8	0
168	Cost-effectiveness of model-based eligibility for lung cancer screening in the routine clinical practice. <i>Annals of Translational Medicine</i> , 2018, 6, 369-369.	0.7	0
169	Immune-related adverse events (irAEs) and survival in solid tumors treated with immune checkpoint inhibitors (ICIs): A systematic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2019, 37, e14130-e14130.	0.8	0
170	Effect of gender on the outcome of patients receiving nivolumab for metastatic renal cancer: Results from a large study population.. <i>Journal of Clinical Oncology</i> , 2019, 37, e16087-e16087.	0.8	0
171	Is adjuvant immunotherapy effective in patients with urothelial cancer?. <i>Minerva Urology and Nephrology</i> , 2022, , .	1.3	0
172	Clinical and pathological prognostic factors in Merkel cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, e21574-e21574.	0.8	0
173	Efficacy of a nurse monitoring service at preventing disease- or therapy-related symptoms in patients receiving targeted therapy or immunotherapy.. <i>Journal of Clinical Oncology</i> , 2022, 40, 12118-12118.	0.8	0